Louis Lange

Dr. Lange is a physician scientist with deep experience in academic medicine and the biotech industry. He currently serves as a General Partner at Asset Management Ventures with a focus on leading healthcare innovation in numerous biotech, genomics, bioinformatics and imaging companies. Dr Lange founded and was Chairman/CEO of CV Therapeutics, Inc. for 19 years, leading the company thorough the commercial launch of Lexiscan and Ranexa®️, a billion dollar first-in-class late sodium channel blocker and the first anti-anginal drug class approved in 30 years. He led the sale of the company to Gilead Sciences for $1.5 billion in 2019 and remained a part-time senior advisor to the CEO of Gilead for a decade. Afterwards he founded several other biotech companies and led two acquisitions, one to GE Healthcare and one to Audentes, where he became Lead Director. Prior to joining the biotech sector, Dr. Lange spent 22 years practicing academic medicine at Harvard University and Washington University. Dr. Lange received his bachelor’s degree from the University of Rochester and holds an M.D. and a Ph.D. in biological chemistry, both obtained from Harvard University.